Staff Contact: Andrew Wheeler
HHS released initial guidance for the Medicare Drug Price Negotiation Program for 2026. The Inflation Reduction Act provided Medicare the ability to negotiate lower prescription drug prices in an attempt to lower drug cost. CMS provided additional information about reduced coinsurance for certain Part B drugs, effective Saturday, April 1. “For the quarter April 1 – June 30, 2023, people with Medicare may experience coinsurance amounts that are lower than what they would have paid before the new law passed by as much as $2 to $390 per average dose.” MHA published an issue brief with details.